title: Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis.
abstract: Cyclosporine is known to be effective in the treatment of psoriasis. In this study, we have used oral cyclosporine (6 mg/kg per day) given for 5 to 30 weeks to 24 patients for the treatment of 12 different dermatoses. Patients with the following diseases demonstrated a marked response or total clearing: 1 patient each with pyoderma gangrenosum, pityriasis lichenoides chronica, and psoriasis of the acrodermatitis continua of Hallopeau type. Moderate to marked response occurred in both patients with epidermolysis bullosa acquisita and the patient with hidradenitis suppurativa. Minimal to moderate responses were obtained in both patients with granuloma annulare, 1 of 2 with acrodermatitis continua of Hallopeau, both patients with Darier's disease, and 1 of 6 patients with vitiligo. Little or no response was noted in both patients with sarcoidosis, all 3 patients with pityriasis rubra pilaris, 5 of 6 patients with vitiligo, 1 patient with pemphigus foliaceous, and 1 with pemphigus vulgaris. Clinical side effects were mild and transient and included dysesthesia, fatigue, hypertrichosis, nausea, and flushing. The most frequent clinically significant abnormalities were hypertension and renal dysfunction, with all factors normalizing within 1 month of discontinuation of cyclosporine therapy.
authors.affiliation: Department of Dermatology, University of Michigan Medical School, Ann Arbor.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: C N
authors.initials: CN
authors.lastname: Ellis
authors.forename: B J
authors.initials: BJ
authors.lastname: Nickoloff
authors.forename: M T
authors.initials: MT
authors.lastname: Goldfarb
authors.forename: V C
authors.initials: VC
authors.lastname: Ho
authors.forename: L L
authors.initials: LL
authors.lastname: Rocher
authors.forename: C E
authors.initials: CE
authors.lastname: Griffiths
authors.forename: K D
authors.initials: KD
authors.lastname: Cooper
authors.forename: J J
authors.initials: JJ
authors.lastname: Voorhees
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003524:Cyclosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003872:Dermatitis / Q000188:drug therapy* / Q000473:pathology; D004820:Epidermolysis Bullosa / Q000188:drug therapy; D005260:Female; D006099:Granuloma / Q000188:drug therapy; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D010915:Pityriasis / Q000188:drug therapy; D011711:Pyoderma / Q000188:drug therapy; D012507:Sarcoidosis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003524:Cyclosporins